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What’s	already	known	about	this	topic?	
• Most	patients	with	acne	self-manage	or	are	managed	in	primary	care.	
• Studies	suggest	low	consultation	rates	and	medication	adherence	for	acne.	
• Longitudinal	care	with	follow-up	appointments	could	improve	medication	use	and	outcomes.	
• Oral	and	topical	antibiotic	use	can	promote	the	development	of	antimicrobial	resistance.	
	
What	does	this	study	add?	
• Two-thirds	of	patients	who	have	a	new	acne	consultation	have	no	follow-up	consultation	during	the	
subsequent	90	days.	
• Oral	antibiotics	are	the	most	common	acne	related	medications	(ARM)	prescribed,	normally	without	co-
prescribing	topical	non-antibiotic	agents.	
	• Following	an	initial	prescription,	60.1%	and	38.6%	of	patients	received	no	further	ARM	prescriptions	in	the	
following	90	days	and	one	year	respectively.	 	
		
	
Abstract	
Background:	Effective	management	of	acne	vulgaris	in	primary	care	involves	support	(usually	provided	over	a	
number	of	consultations)	and	prescribing	effective	treatments.	However,	consulting	and	prescribing	patterns	for	
acne	in	primary	care	are	not	well	described.	
Objective:	To	describe	the	rate	of	primary	care	consultations	and	follow-up	consultations;	prescribing	patterns,	
including	overall	use	of	acne	related	medications	(ARM)	and	initial	and	follow-up	prescribing,	for	acne	vulgaris	in	
the	UK.	
Methods:	UK	primary	care	acne	consultations	and	prescriptions	for	ARMs	were	identified	in	the	Clinical	Practice	
Research	Datalink	(CPRD).	Annual	consultation	rates	(between	2004	and	2013)	by	age	and	gender,	new	
consultations	and	consultations	in	the	subsequent	year;	prescribing	trends,	prescribing	during	a	new	consultation	
and	over	the	subsequent	90	days	and	year	were	calculated,	using	number	of	registered	patients	as	the	
denominator.	
Results:	65.9%	of	patients	who	had	a	new	acne	consultation	had	no	further	acne	consultations	in	the	subsequent	
year.	26.6%,	25.2%,	23.5%	and	2.8%	of	patients	were	prescribed	no	ARM,	an	oral	antibiotic,	a	topical	antibiotic,	or	
an	oral	plus	topical	antibiotic	respectively	during	a	new	acne	consultation.	59.9%	and	38.5%	of	patients	prescribed	
an	ARM	received	no	further	ARM	prescriptions	in	the	following	90	days	and	one	year	respectively,	despite	most	
prescriptions	being	for	2	months	or	less.	Prescribing	rates	for	lymecycline	and	topical	combined	
clindamycin/benzoyl	peroxide	increased	substantially	between	2004	and	2013.	There	were	no	important	changes	
in	consultation	rates	between	2004	and	2013.	
Conclusion:	These	data	suggest	that	patients	with	acne	are	receiving	sub-optimal	initial	choice	of	ARMs,	
longitudinal	care	and	prescribing.		
	 	
	INTRODUCTION		
Acne	vulgaris	(‘acne’	hereafter)	is	one	of	the	most	common	dermatological	conditions	managed	by	health	services	
in	the	developed	world.1	It	has	a	significant	impact	on	quality	of	life2,3	and	is	associated	with	mental	health	problems	
and	suicide.1,4		Acne	is	a	chronic	condition	that	usually	begins	in	the	early	teens	and	is	present	in	over	40%	of	those	
in	their	thirties.5	In	the	UK,	most	medical	care	for	people	with	acne	is	provided	in	primary	care.	
Acne	can	be	effectively	treated	with	a	range	of	antibiotic	and	non-antibiotic	approaches.	However,	for	medications	
to	be	effective	they	need	to	be	used	regularly.	Little	is	known	about	how	frequently	acne	medications	are	initiated,	
and	once	started,	for	how	long	they	are	used.	Most	of	these	medications	have	a	slow	onset	of	action	and	need	to	be	
used	for	several	weeks	or	months	before	full	effectiveness	is	seen.	Therefore,	it	is	important	to	ensure	that	patients	
receive	adequate	information	about	use	of	the	medication,	and	ideally	monitoring	and	support	to	encourage	ongoing	
use	(for	at	least	3-4	months).	Guidance	for	clinicians	recommends	close	monitoring	and	follow-up	appointments.	6,7	
Consulting	 in	primary	 care	 for	 acne	allows	 for	 accurate	diagnosis	 and	 assessment	of	 severity;	 an	opportunity	 to	
discuss	the	evidence	for	effectiveness	of	various	treatments,	seek	the	patient’s	ideas	and	expectations,	dispel	myths,	
and	come	to	a	shared	decision	regarding	a	treatment	plan;	and	education	about	the	slow	onset	of	action	of	most	
acne	medications	and	the	need	 for	prolonged	treatment.	Early	 follow-up	consultations	are	recommended	by	UK	
guidelines6	and	are	important	in	order	to	provide	ongoing	support	and	encourage	regular	use	of	medication,	monitor	
for	 adverse	effects	 and	provide	advice	 about	 changes	 to	 treatment	 regimens	where	necessary;	 and	monitor	 for	
adverse	psychological	impacts.	However,	it	is	not	clear	how	often	patients	consult	in	primary	care,	both	in	terms	of	
new	 consultations	 and	 follow-up	 consultations.	 In	 addition,	 there	 are	 few	 data	 about	medications	 primary	 care	
clinicians	prescribe	for	acne	and	how	frequently	they	are	prescribed	to	an	individual	patient.	There	are	increasing	
concerns	 about	 the	 development	 of	 antibiotic	 resistance	 in	 acne,8	 and	 UK	 guidelines	 recommend	 restricting	
antibiotics	to	second	or	third	line	treatments	and	combining	oral	antibiotics	with	topical	treatments	such	as	benzoyl	
peroxide	(to	reduce	resistance),	or	retinoids	or	adapalene	(to	reduced	comedones).	6,7	
We	 set	 out	 to	 determine	 the	 rates	 and	 trends	 in	 primary	 care	 consultations	 for	 acne,	 and	 the	 frequency	 of	
subsequent	(follow-up)	acne	consultations	in	a	patient	who	has	had	a	new	(index)	consultation	for	acne.	In	addition,	
we	aimed	to	determine	which	medications	are	prescribed	in	primary	care	for	acne,	how	these	have	changed,	and	
the	patterns	of	prescribing	during	the	year	following	an	index	consultation.		
METHODS	
This	retrospective	longitudinal	cohort	study	of	patients	presenting	to	their	General	Practice	with	acne	vulgaris	makes	
use	 of	 UK	 Clinical	 Practice	 Research	 Datalink	 (CPRD)	 data.9	 This	 large	 database	 of	 anonymised	 patient	 records	
represents	approximately	9%	of	the	UK	population.	Data	are	extracted	from	over	500	primary	care	practices	across	
the	UK	representing	over	5.5	million	individuals.10	For	this	study,	data	were	extracted	on	patients	who	consulted	with	
any	acne	read-code	between	01/01/04	and	31/12/13.		Read	codes	included	acne	varioliformis,	acne	frontalis,	acne	
	necrotica,	other	acne,	acne	vulgaris,	blackhead,	acne	conglobate	and	cystic	acne.	We	excluded	unusual	codes	such	
as	acne	fulminans,	chlorine	acne,	iodine	acne,	and	colloid	acne.		We	also	excluded	children	aged	less	than	8	years	
and	codes	for	acne	neonatorum	and	infantile	acne	as	pre-pubertal	acne	is	uncommon	and	usually	non-inflammatory,	
and	we	excluded	those	with	no	gender	identified	in	the	data.	At	each	consultation	point,	patients	were	classified	into	
one	of	four	age	bands	(8-11	years,	12-18	years,	19-29	years	and	30	or	more	years	of	age).	We	did	not	restrict	on	the	
basis	of	recorded	consultation	type	(i.e.	surgery	consultation,	telephone	consultation,	home	visit).	CPRD	undertake	
data	 quality	 checks	 and	 flag	 patients	 as	 having	 acceptable	 data	 or	 not.	 For	 all	 analyses,	 and	 for	 calculating	
denominators,	we	only	used	patients	who	had	been	flagged	as	having	acceptable	data.	
Consultation	rates	
Age	and	gender	specific	consultation	rates	per	1,000	person-years	were	calculated	using	age	and	gender	specific	
denominators	calculated	based	on	patients	registered	with	CPRD	practices	during	the	same	time	period.	The	number	
of	registered	patients	during	each	month	was	averaged	over	each	study	year.	Annual	age	and	gender	specific	rates	
were	plotted	for	2004	–	2013,	and	average	annual	rates	were	tabulated.	
In	order	 to	better	describe	acne	consultation	patterns	 following	an	 initial	 consultation,	we	 identified	a	cohort	of	
patients	with	an	‘index’	acne	consultation	occurring	between	2005	and	2012,	no	acne	consultations	and	no	primary	
care	prescriptions	for	acne	related	medications	(ARM;	see	prescribing	section	for	list	of	ARMs)	in	the	year	prior	to	
their	index	consultation,	and	at	least	a	year	of	follow-up	data	available	after	their	index	consultation	(patients	who	
died	or	transferred	to	a	different	surgery	during	their	follow-up	year	were	excluded).	We	then	followed	each	patient	
for	the	year	following	their	index	consultation	and	counted	the	number	of	subsequent	acne	consultations,	and	time	
to	first	subsequent	acne	consultation,	for	each	participant.		
Prescribing	
Prescribing	was	assessed	by	examining	the	following	as	ARMs	based	on	guidance	in	the	British	National	Formulary	
(BNF)(11):	 oral	 oxytetracycline,	 tetracycline,	 doxycycline,	 lymecycline,	 minocycline	 and	 erythromycin;	 topical	
antibiotics	(erythromycin	or	clindamycin),	topical	retinoid	(and	retinoid-like)	preparations,	topical	benzoyl	peroxide	
and	azelaic	acid,	and	topical	combination	products;	and	co-cyprindiol	 (Dianette).	Prescriptions	for	oral	antibiotics	
that	were	for	less	than	28	days	and	erythromycin	suspensions	were	excluded	because	these	are	less	likely	to	have	
been	prescribed	for	acne.	Combined	oral	contraceptives	other	than	co-cyprindiol	can	be	used	for	treating	acne,	but	
were	not	 included	because	they	are	commonly	prescribed	for	contraception	or	menstrual	problems	and	 it	 is	not	
possible	using	CPRD	data	to	determine	whether	they	were	being	prescribed	for	acne	or	not.	Relevant	items	were	
grouped	together	on	the	basis	of	their	active	ingredient(s).	ARMs	that	were	prescribed	during	the	ten-year	study	
period	were	identified	for	all	patients	who	had	one	or	more	Read	codes	for	acne	at	any	point	during	the	ten-year	
period,	whether	they	occurred	at	the	time	of	an	acne	consultation	or	not.	Total	annual	ARM	prescription	rates	were	
calculated	and	plotted	for	each	ARM.	
	To	further	describe	the	pattern	of	ARM	use,	we	used	the	cohort	with	an	index	consultation	and	at	least	a	year	of	
follow-up	data	available	described	earlier.	We	calculated	the	number	and	type	of	ARMs	that	were	prescribed	at	the	
index	consultation,	during	the	subsequent	90	days,	and	during	the	subsequent	year.	We	classified	each	ARM	into	
one	 of	 the	 following	 four	 groups:	 topical	 antibiotic,	 topical	 non-antibiotic,	 oral	 antibiotic	 and	 co-cyprindiol.	
Consultations	were	then	classified	as	involving	prescription	of	one	of	the	four	groups	described	above	or	one	of	the	
following	combinations:	oral	antibiotic	+	topical	non-antibiotic,	oral	antibiotic	+	topical	antibiotic,	co-cyprindiol	+	any	
topical	agent,	and	other	combinations.	Along	with	 ‘no	ARM’,	this	resulted	 in	nine	groups.	We	then	identified	the	
prescribing	 group	 for	 each	 index	 consultation	 and	 the	 changes	 in	 group	 (including	 to	 ‘no	 ARM’)	 during	 the	
subsequent	90	days	and	364	days.	Prescribing	at	the	index	consultation	and	changes	during	the	first	90	days	were	
then	plotted	using	a	Sankey	diagram.
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	Finally,	we	identified	the	quantity	of	medication	prescribed	for	each	ARM,	
and	described	the	median	and	interquartile	range.	Oral	antibiotic	prescriptions	where	the	quantity	prescribed	was	
greater	than	672	(equivalent	to	four	times	a	day	for	six	months)	were	excluded	as	these	were	thought	likely	to	be	
errors.	
This	 study	 was	 approved	 by	 the	 Independent	 Scientific	 Advisory	 Committee	 (Refs:	 14-095	 and	 14-096),	 the	
independent	body	that	approves	use	of	CPRD	data.	Study	protocols	and	programing	code	can	be	made	available	
upon	request.	Stata	statistical	software	(version	13)	was	used	for	all	analyses.
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RESULTS	
Consultation	Rates	
318,772	patients	had	been	assigned	a	code	for	acne	at	some	point	during	2004	–	2013.	We	removed	230	(0.07%)	
patients	who	had	no	consultations	where	they	were	aged	8	or	over	and	7	patients	with	missing	data	on	gender,	
leaving	716,272	consultations	in	318,535	patients.	The	highest	consultation	rates	were	found	in	12-18	year	old	girls,	
followed	by	12-18	year	old	boys,	19-29	year	old	women	and	19-29	year	old	men	(Table	1	and	Fig.	1).	Consultation	
rates	were	low	for	8-11	year	olds	and	those	aged	30	or	over.	There	did	not	appear	to	be	any	significant	trends	in	
consultation	rates	over	the	period	from	2004	to	2013	(Fig.	1).	
Re-consultations	
167,573	patients	aged	8	years	or	over	met	the	criteria	for	inclusion	in	the	cohort.	Of	these,	66.1%	had	no	further	
acne	consultations	during	the	following	year,	21.8%	had	one,	and	12.1%	had	two	or	more.	Of	those	who	did	have	a	
subsequent	acne	consultation	during	the	following	year,	more	than	half	(55.5%)	occurred	after	first	90	days,	and	
there	was	slightly	less	early	follow-up	in	younger	patients	(Table	2).	
Prescribing	
Out	of	the	318,535	patients	over	8	who	had	had	one	or	more	acne	consultations,	41,185	(12.9%)	were	not	prescribed	
any	ARMs	during	2004	–	2013,	leaving	277,350	(87.1%)	who	were	prescribed	2,081,351	ARM	prescriptions	during	
	the	ten-year	period.	Oxytetracyline	was	the	most	common	ARM	to	be	prescribed	in	2004	(6.5	items	per	1,000	PY),	
but	lymecycline	prescribing	increased	substantially	over	the	study	period,	and	became	the	most	common	oral	ARM	
from	2008	(11.8	 items	per	1,000	PY	in	2013)(Fig.	2).	Doxycycline	prescribing	increased	to	a	 lesser	extent	and	the	
prescribing	of	all	other	oral	antibiotics	and	co-cyprindiol	decreased	over	the	study	period.	The	prescribing	of	oral	
isotretinoin	increased	ten-fold	from	0.01	to	0.1	items	per	1,000	PY	from	2004	to	2009,	but	then	decreased	slightly	
to	0.8	items	per	1,000	PY	in	2013.	The	most	commonly	prescribed	topical	agent	in	2004	was	clindamycin	(3.1	items	
per	1,000	PY),	but	prescribing	of	topical	combined	clindamycin	and	benzoyl	peroxide(Duacä)	increased	substantially	
over	the	study	period	and	was	the	most	commonly	prescribed	topical	ARM	from	2008	on	(8.8	items	per	1,000	PY	in	
2013)(Fig.	3).	
	
A	total	of	167,573	patients	aged	8	or	over	were	identified	as	having	a	new	acne	consultation	(index	consultation),	
with	no	prior	acne	consultations	or	ARM	prescriptions	in	the	previous	12	months.	26.7%	of	these	were	prescribed	
no	ARM	during	their	index	consultation.	The	most	common	ARM	prescribed	during	the	index	consultation	was	oral	
antibiotic	 alone	 (24.9%	 of	 consultations).	 The	 frequency	 of	 prescribing	 other	 ARM	 combinations	 at	 the	 index	
consultation	is	given	in	Table	3.	67.5%	of	patients	were	prescribed	no	ARMs	during	the	90	days	following	the	index	
consultation.	A	third	of	these	(39,314)	were	not	prescribed	an	ARM	at	the	index	consultation	as	well	as	not	being	
prescribed	an	ARM	in	the	following	90	days.	Nearly	half	(20,481	(49.0%))	of	those	prescribed	an	oral	antibiotic	at	the	
index	consultation	had	no	further	ARM	prescriptions	in	the	following	90	days,	and	the	majority	of	those	prescribed	
topical	antibiotics	(27,670	(70.0%))	and	topical	non-antibiotics	(15,926	(76.3%))	were	prescribed	no	further	ARMs	in	
the	 following	90	days.	 Figure	4	gives	a	graphical	 representation	of	which	ARMs	 (or	 combinations)	patients	were	
prescribed	at	baseline	and	in	the	following	90	days.	78,567	(46.9%)	patients	were	prescribed	no	ARMs	during	the	
year	 following	 their	 index	 consultation.	 Of	 the	 122,764	 patients	 who	 were	 prescribed	 an	 ARM	 at	 their	 index	
consultation,	73,817	(60.1%)	and	47,408	(38.6%)	were	prescribed	no	further	ARMs	during	the	subsequent	90	days	
and	year	respectively.	Very	few	patients	were	prescribed	oral	isotretinoin,	either	at	the	index	consultation	or	during	
the	following	year.	
	
The	quantity	of	ARMs	per	prescription	was	approximately	equivalent	to	2-3	months’	worth	for	most	patients	(Table	
4).		
	
	
DISCUSSION	
Summary	of	main	findings	
In	this	analysis	of	routinely	collected	UK	general	practice	data	we	found	that	consultation	rates	for	acne	in	primary	
care	are	relatively	low,	and	were	largely	stable	between	2004-2013.	Using	population	distribution	data	from	2013,	
our	data	suggest	that	there	are	around	934,000	general	practitioner	(GP)	consultations	for	acne	a	year,	and	that	a	
	typical	general	practice	of	7,000	patients	would	expect	to	have	115	consultations	for	acne	per	year:	1	with	8-11	year	
olds,	25	with	12-18	year	old	boys,	29	with	12-18	year	old	girls,	13	with	19-29	year	old	men,	28	with	19-29	year	old	
women,	4	with	men	aged	30	or	more	and	15	with	women	aged	30	or	more.	Only	one-third	of	patients	who	have	a	
new	 acne	 consultation	 (no	 acne	 consultations	 or	 prescriptions	 in	 the	 preceding	 year)	 have	 a	 follow-up	 acne	
consultation	in	the	subsequent	year.	A	quarter	of	patients	with	a	new	acne	consultation	are	prescribed	no	ARMs	
during	 their	 initial	 consultation,	 two-thirds	 receive	 no	 ARMs	 during	 the	 following	 three	 months	 (even	 though	
quantities	prescribed	are	generally	for	less	than	3	months),	and	only	about	a	half	receive	one	or	more	ARMs	in	the	
subsequent	year.	Oral	antibiotics	(without	any	prescribed	topical	medication)	were	the	most	common	ARM	to	be	
prescribed	at	the	first	consultation,	followed	by	topical	medication	containing	antibiotics	and	then	topical	medication	
without	 antibiotics.	 Oxytetracycline	 was	 the	 most	 commonly	 prescribed	 oral	 ARM	 in	 2004,	 but	 prescribing	 of	
lymecycline	increased	steadily	throughout	the	period	up	to	2013,	and	became	the	most	common	oral	ARM	from	
2009	on.	Co-cyprindiol	prescribing	decreased	slightly	over	the	same	period.	Oral	isotretinoin	was	rarely	prescribed	
initially,	but	use	 increased	ten-fold	between	2004-2009.	Clindamycin	was	 the	most	commonly	prescribed	topical	
ARM	in	2004,	but	prescribing	of	topical	combined	clindamycin/BPO	increased	about	five-fold	during	the	period	under	
study,	and	topical	combined	clindamycin/BPO	was	the	most	commonly	prescribed	topical	ARM	from	2007	on.	Most	
non-antibiotic	ARMs	were	prescribed	at	relatively	low	rates,	but	prescribing	of	the	third	generation	topical	retinoid,	
adapalene	(as	a	single	agent)	and	combined	adapalene/BPO	(Epiduoä)	increased	from	around	2010/11	on.	
Our	study	included	a	large	representative	sample	and	data	from	across	England	and	Wales.	We	were	able	to	use	
data	for	a	ten-year	period	allowing	for	a	description	of	consultation	and	prescribing	rate	trends	over	time.	We	were	
able	to	account	for	patients	joining	or	leaving	practices	in	our	denominators,	and	this	 is	significant	as	29%	of	the	
patients	consulting	for	acne	transferred	out	of	the	practice	before	2013	and	38%	of	the	patients	in	our	study	joined	
the	practice	between	2004	and	2013.	CPRD	uses	data	collected	as	part	of	routine	clinical	care,	and	therefore	the	
data	may	not	always	be	relevant	for	research	purposes.	We	did	not	exclude	on	the	basis	of	consultation	type	and	
therefore	 may	 have	 included	 some	 out-of-hours,	 secondary	 care	 or	 spurious	 consultations	 as	 primary	 care	
consultations.	This	is	unlikely	to	have	been	a	frequent	occurrence,	but	our	consultation	rates	and	follow-up	rates	
may	 be	 a	 slight	 overestimate	 of	 actual	 rates.	 Prescribing	 data	 are	 well	 coded	 in	 UK	 primary	 care,	 however	
prescriptions	are	not	directly	linked	to	a	diagnosis	(they	are	linked	to	a	‘consultation’,	which	may	or	may	not	have	
one	or	more	diagnostic	codes),	and	therefore	we	cannot	be	certain	that	all	prescriptions	were	actually	for	acne.	Most	
ARMs	are	fairly	specific	for	acne,	but	oral	antibiotics	could	have	been	prescribed	for	other	indications.	We	dealt	with	
this	by	identifying	a	cohort	of	patients	with	a	‘new’	acne	consultation	and	at	least	a	year	of	follow-up	data,	following	
them	over	a	year,	and	by	only	including	prescriptions	of	oral	antibiotics	that	were	for	28	days	or	more.	The	Read	
code	system	that	is	used	in	UK	primary	care	does	not	allow	for	coding	of	severity	or	site,	and	so	we	are	not	able	to	
present	data	on	this.	We	excluded	prescriptions	for	oral	antibiotics	that	were	for	less	than	28	tablets	(equivalent	to	
7	days)	and	oral	erythromycin	suspensions,	as	most	of	these	are	unlikely	to	be	for	acne.	However,	it	is	possible	that	
some	of	these	prescriptions	were	for	acne.	Topical	treatments	containing	BPO	are	available	without	a	prescription	
	in	the	UK,	so	it	is	possible	that	some	of	the	patients	who	appear	to	be	using	‘no	ARMs’	are	actually	using	over	the	
counter	BPO.	Combined	oral	contraceptives	(COC)	are	not	licensed	for	use	in	acne	(apart	from	co-cypriniol	which	is	
licensed	for	severe	acne)	in	the	UK,	but	are	known	to	be	effective	and	are	likely	to	have	been	prescribed	for	acne	in	
some	patients.	However,	UK	primary	care	data	do	not	link	indications	to	prescriptions	and	therefore	it	is	impossible	
to	determine	which	COC	were	prescribed	for	acne	and	which	were	not.	
Our	estimate	of	 acne	consultation	 rates	 suggests	 a	 total	number	of	primary	 care	 consultations	 (934,000)	 that	 is	
considerably	lower	than	the	3.5	million	consultations	per	year	that	has	been	cited	in	a	number	of	publications.
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The	 latter	seems	to	have	been	extrapolated	from	data	 from	a	small	 (180	patients)	French	study	of	patients	with	
severe	acne,	and	therefore	is	unlikely	to	be	representative	of	consulting	behaviour	for	acne	of	all	severities	in	the	
UK.
16
	Diagnoses	are	not	always	well	 recorded	 in	primary	care	data,
17
	 and	 follow-up	consultations	may	use	non-
specific	codes	like	‘patient	reviewed’	instead	of	a	diagnostic	code.	Therefore,	our	data	may	underestimate	the	true	
incidence	of	primary	care	consultations	for	acne,	and	the	follow-up	rate	following	an	initial	consultation.	However,	
Purdy	et	al.	used	similar	primary	care	data	in	their	study,	and	they	undertook	a	validation	process	which	found	no	
primary	care	consultations	for	acne	that	had	not	been	coded.
18
	Therefore,	it	seems	likely	that	our	data	represent	
the	 most	 accurate	 estimate	 of	 primary	 care	 consultation	 rates	 for	 acne	 in	 the	 UK.	 There	 are	 few	 reliable	
measurements	of	overall	acne	prevalence	in	the	UK,	but	if	we	use	prevalence	rates	from	the	United	States
19
	we	can	
calculate	an	estimated	total	UK	prevalence	of	around	8.1	million,	suggesting	that	in	any	given	year	there	is	only	1	
primary	care	consultation	 for	every	8-9	patients	with	acne.	This	seems	broadly	consistent	with	a	study	of	school	
children	that	found	that	less	than	a	third	of	those	with	definite	acne	had	ever	consulted	a	doctor.
20
	
A	previous	retrospective	cohort	study	examined	acne	incidence	using	primary	care	records.	They	extracted	data	from	
14	general	practices	in	northeast	England	and	reported	an	incidence	of	first	consultations	in	13-25	year	olds	over	12	
months	of	1.6%	(16	per	1,000	person-years),	and	a	period	prevalence	(over	12	months)	of	acne	(defined	as	anyone	
consulting	or	receiving	medication	for	acne)	of	3.1%.
18
	Our	consultation	rates	of	75.2	and	92.8	consultations	per	
1,000	patient	years	for	12-18	year-old	boys	and	girls	respectively	are	clearly	higher,	but	reflect	total	consultations	
rather	 than	 just	 first	 consultations.	 Our	 finding	 that	 the	 highest	 consultation	 rates	 are	 amongst	 teenagers	 is	
consistent	with	other	studies,	
18,21-23	but	we	were	also	able	to	demonstrate	that	a	considerable	number	of	patients	
aged	30	years	or	over	(especially	women)	consult	for	acne.		
The	same	cohort	study	reported	that	in	2001/02	just	over	50%	of	males	and	a	third	of	females	were	prescribed	oral	
antibiotics	first	line,	between	a	third	and	a	quarter	of	males	and	females	were	prescribed	non-antibiotic	topical	ARMs	
first	 line,	 and	 about	 20%	 of	males	 and	 a	 quarter	 of	 females	were	 prescribed	 topical	 antibiotics	 first	 line.
18
	 The	
proportion	 who	 were	 prescribed	more	 than	 one	medication	 was	 not	 described	 in	 this	 study,	 but	 the	 data	 are	
compatible	with	our	finding	that	a	large	proportion	of	patients	are	treated	with	oral	antibiotics	first	line.		We	have	
not	been	able	to	identify	any	other	studies	looking	at	follow-up	consultations	and	ongoing	prescribing,	however	an	
	international	cross-sectional	survey	of	patients	attending	a	follow-up	appointment	(1-3	months	after	a	preceding	
acne	consultation)	identified	that	58%	of	patients	in	Europe	had	poor	adherence	to	acne	medication.
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The	natural	history	of	acne	is	not	well	described	as	there	is	a	lack	of	high	quality	prospective	cohort	studies.	However,	
acne	is	largely	considered	to	be	a	chronic	condition,	with	cross-sectional	studies	showing	onset	in	the	teenage	years	
and	persistence	 into	 the	 thirties	 of	 forties	 for	many	patients.1	 As	 a	 chronic	 condition,	 and	especially	 one	where	
medication	can	take	weeks	or	months	to	achieve	maximal	effect,
25
	and	myths	and	misperceptions	are	common,
26
	
ongoing	care	in	the	form	of	follow-up	appointments	is	important.	National	Institute	for	Health	and	Care	Excellence	
(NICE)	Clinical	Knowledge	Summaries	 (CKS)	guidance	suggests	that	patients	should	be	reviewed	after	six	 to	eight	
weeks	to	assess	treatment	response	and	provide	support.6	Therefore,	our	finding	that	two-thirds	of	patients	have	
no	follow-up	consultations	in	the	subsequent	year,	and	that	the	majority	of	those	that	do	consult	do	so	more	than	
three	months	 after	 their	 initial	 consultation	 (which	 is	 longer	 than	 the	 typical	 duration	of	 treatment	prescribed),	
suggest	that	longitudinal	acne	care	may	be	suboptimal	in	primary	care.	Some	patients	may	have	had	mild	acne	and	
just	wanted	reassurance,	and	others	may	have	been	happy	to	use	over	the	counter	treatment	and	have	no	follow-
up.	Without	data	on	severity	it	is	not	possible	to	determine	the	proportion	falling	into	this	category,	but	as	three-
quarters	of	new	acne	consultations	involved	prescribing	an	ARM	and	around	a	third	of	those	being	prescriptions	for	
oral	antibiotics,	the	numbers	are	unlikely	to	be	high.		Some	may	have	been	referred	on	to	secondary	care	and	this	
may	explain	their	lack	of	follow-up	in	primary	care.	We	did	not	extract	data	on	referrals,	but	Purdy	et	al.	reported	
that	only	8.5%	of	patients	were	referred	over	a	two-year	follow-up	period,
18
	so	referral	is	unlikely	to	account	for	a	
large	proportion	of	the	patients	who	had	no	follow-up.	Furthermore,	we	found	that	60%	of	patients	who	are	started	
on	one	or	more	ARMs	were	not	prescribed	any	further	ARMs	in	the	subsequent	90	days.	It	is	possible	that	some	of	
these	patients	had	a	rapid	resolution,	and	others	may	have	moved	on	to	using	over	the	counter	products,	however	
these	data	suggest	that	a	large	proportion	discontinued	or	poorly	adhered	to	treatment	before	giving	it	sufficient	
opportunity	to	work.	GPs	have	been	encouraged	to	limit	use	of	antibiotics	and	this	may	have	contributed	to	the	short	
duration	of	oral	antibiotic	prescribing.	However,	most	guidance	suggests	that	antibiotic	treatment	should	be	for	at	
least	3-4	months,
27
	and	that	maintenance	therapy	with	topical	non-antibiotic	treatments	should	be	continued	or	
initiated	after	oral	antibiotics	are	stopped.	Our	data	suggest	limited	use	of	prescription	non-antibiotic	treatments,	
either	as	single	agents	or	in	combination	with	oral	antibiotics.		
Around	a	third	of	patients	with	a	new	acne	consultation	who	were	treated	with	an	ARM	were	prescribed	only	an	oral	
antibiotic,	a	further	third	were	prescribed	only	a	topical	antibiotic,	and	another	11%	were	prescribed	both	an	oral	
antibiotic	 and	 a	 topical	 agent.	 Therefore,	 in	 total,	 just	 over	 three-quarters	 of	 initial	 acne	 therapy	 included	 an	
antibiotic.	 NICE	 CKS	 guidance	 for	 moderate	 acne	 recommends	 considering	 oral	 antibiotics	 only	 when	 there	 is	
extensive	or	difficult	to	reach	acne	on	the	back	or	when	there	is	a	significant	risk	of	scaring	or	pigment	change,	and	
indicates	that	they	should	be	combined	with	topical	non-antibiotics.6	We	do	not	know	the	severity,	extent,	or	location	
of	the	acne	in	this	study,	and	we	do	not	know	how	many	patients	were	using	topical	agents	that	they	purchased	over	
	the	counter.	Nevertheless,	these	data	suggest	significant	overuse	of	antibiotics	in	general	and	underuse	of	topical	
non-antibiotic	 treatment	 in	 those	 prescribed	 oral	 antibiotics.	 This	 is	 an	 important	 concern,	 given	 the	 increasing	
prevalence	of	resistant	P	acnes,8	and	the	effects	of	antibiotic	use	for	acne	on	resistance	in	other	commensals
28
	and	
the	 development	 of	 respiratory	 tract	 infections.
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	 Our	 finding	 that	 oral	 tetracyclines	 were	 the	most	 commonly	
prescribed	oral	antibiotics	is	consistent	with	guidance.6	There	is	good	quality	evidence	supporting	the	use	of	BPO	
and	topical	retinoid	alone	or	combined	with	a	topical	antibiotic,	and	these	agents	are	recommended	in	guidelines.6,7	
BPO	is	an	effective	antimicrobial,	but	does	not	promote	the	development	of	resistance,	and	topical	retinoids	play	an	
important	role	in	acne	management	because	of	their	role	in	preventing	comedogenesis.	The	increasing	use	of	topical	
combined	clindamycin/BPO)		is	therefore	consistent	with	evidence,	but	the	low	use	of	topical	retinoid	and	BPO	that	
we	found	is	concerning.	Again,	we	have	no	information	about	how	many	of	these	patients	were	using	topical	agents	
purchased	over	the	counter,	but	our	data	do	suggest	significant	under-use	of	these	agents.	
In	conclusion,	our	data	suggest	that	the	management	of	acne	in	primary	care	is	sub-optimal	and	that	consultation	
rates	are	relatively	low	for	such	a	common	condition.	Management	is	over-reliant	on	antibiotic	treatment	(especially	
oral	antibiotics)	and	under-utilises	non-antibiotic	treatments;	oral	antibiotics	are	frequently	prescribed	and	in	most	
cases	they	are	prescribed	without	co-prescribing	topical	non-antibiotic	treatments	(increasing	the	risk	of	resistance	
and	in	contravention	to	guidelines),	treatment	courses	are	too	short,	and	follow-up	is	less	than	optimal.	Interventions	
to	improve	the	management	of	acne	in	primary	care	need	to	be	urgently	developed	and	evaluated.		
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TABLES	
Table	1	–	Acne	consultations	per	1,000	person-years	by	age	and	gender:	2004-2013	
Group	
Average	
consultation	rate	
8-11	Male	 0.8	
8-11	Female	 4.8	
12-18	Male	 75.2	
12-18	Female	 92.8	
19-29	Male	 25.5	
19-29	Female	 53.5	
30+	Male	 1.9	
30+	Female	 6.4	
	
	 	
	Table	2	–	Time	to	first	follow-up	consultation	by	age	group	
Time	to	next	
consultation	
Age	Group	
Total	
8	to	11	 12	to	18	 19	to	29	 30+	
Within	30	days	 72	(7.6)	 3,423	(10.0)	 1,842	(12.9)	 1,085	(15.3)	 6,422	(11.3)	
31	to	60	days	 107	(11.4)	 6,301	(18.3)	 2,737	(19.1)	 1,406	(19.9)	 10,551	(18.6)	
61	to	90	days	 90	(9.5)	 4,940	(14.4)	 2,171	(15.2)	 1,062	(15.0)	 8,263	(14.6)	
91	days	to	6	
months	
248	(26.3)	 8,091	(23.5)	 3,421	(23.9)	 1,643	(23.2)	 13,403	(23.6)	
6	months	to	1	
year	
426	(45.2)	 11,644	(33.9)	 4,138	(28.9)	 1,886	(26.6)	 18,094	(31.9)	
Total	 943	 34,399	 14,309	 7,082	 56,733	
	
	 	
	Table	3	–	Acne	related	medications	prescribed	at	an	index	acne	consultation	and	during	the	subsequent	90	days	and	
one	year	
ARM(s)	prescribed	
Prescribing	at	index	
consultation		
Prescribing	during	
subsequent	90	days	
Prescribing	during	year	
following	index	consultation	
(including	first	90	days)	
N	 %*	 %#	 N	 %*	 %#	 N	 %*	 %#	
No	ARM	 44,809	 26.7	 -	 113,131	 67.5	 -	 78,567	 46.9	 -	
Oral	antibiotic	
alone	
41,791	 24.9	 34.0	 25,793	 15.4	 47.4	 32,750	 19.5	 36.8	
Topical	antibiotic	
(including	
combinations)	
alone	
39,529	 23.6	 32.2	 11,004	 6.6	 20.2	 16,806	 10.0	 18.9	
Topical	non-
antibiotic	alone	
20,875	 12.5	 17.0	 4,250	 2.5	 7.8	 6,458	 3.9	 7.3	
Oral	antibiotic	+	
topical	non-
antibiotic	
9,168	 5.5	 7.5	 5,711	 3.4	 10.5	 12,009	 7.2	 13.5	
Oral	antibiotic	+	
topical	antibiotic	
4,671	 2.8	 3.8	 3,666	 2.2	 6.7	 11,215	 6.7	 12.6	
Co-cyprindiol	
alone	
4,014	 2.4	 3.3	 2,433	 1.5	 4.5	 3,987	 2.4	 4.5	
Co-cyprindiol	+	
any	topical	agent	
793	 0.5	 0.6	 564	 0.3	 1.0	 2,265	 1.4	 2.5	
Oral	isotretinoin	
alone	
15	 0.0	 0.0	 36	 0.0	 0.1	 47	 0.0	 0.1	
Oral	isotretinoin	+	
other	ARM	
2	 0.0	 0.0	 8	 0.0	 0.0	 98	 0.1	 0.1	
Other	combination	 1,906	 1.1	 1.6	 977	 0.6	 1.8	 3,371	 2.0	 3.8	
Total	 167,573	 100	 100	 167,573	 100	 100	 167,573	 100	 100	
*	Proportion	of	total	
#	Proportion	of	those	who	were	prescribed	an	ARM	
	
	 	
	Table	4	–	Quantity	of	ARM	medication	prescribed	per	prescription	
Medication	 Quantity	per	
prescription	–	
median	(IQR)	
Equivalent	
number	of	days	
(approximately)*	
Oral	antibiotics	
Oxytetracycline	 112	(112,	120)	 28	
Doxycycline	 50	(28,	56)	 25	
Lymecycline	 56	(28,	56)	 56	
Minocycline	 56	(56,	56)	 28	
Other	tetracyclines	 112	(56,	112)	 28	
Erythromycin	 100	(42,	112)	 25#	
Oral	hormonal	
Co-cyprindiol	 63	(63,	126)	 84	
Topical	
Clindamycin	 50	(30,	50)	 50	
Erythromycin	 50	(50,	50)	 50	
Clindamycin/BPO	 25	(25,	50)	 50	
Erythromycin/retinoid	 30	(25,	47)	 30-60	
BPO	 40	(40,	60)	 40-80	
BPO/hydroxyquinolone	 50	(25,	50)	 33-50	
Azelaic	acid	 30	(30,	30)	 30-60	
Retinoids	 60	(30,	60)	 60-120	
Adapalene	 45	(45,	45)	 90	
Adapalene/BPO	 45	(45,	45)	 90	
*For	topical	agents	a	rough	guide	of	0.5g	(equivalent	to	the	size	of	two	
palm	areas)	per	application	was	used	
#	87%	of	erythromycin	tablets	were	250mg	
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